- Home
- BOLD vs CUE Comparison
BOLD vs CUE Comparison
Compare BOLD & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | CUE |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 27.8M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BOLD | CUE |
|---|---|---|
| Price | $1.12 | $0.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $4.00 | $3.00 |
| AVG Volume (30 Days) | 63.7K | ★ 442.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.47 | ★ 35.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.96 | $0.23 |
| 52 Week High | $1.78 | $1.05 |
Technical Indicators
Market Signals| Indicator | BOLD | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 39.65 |
| Support Level | $1.10 | $0.27 |
| Resistance Level | $1.20 | $0.36 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 14.60 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.